Literature DB >> 27305646

What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey.

Laura B von Kobyletzki1, Kim S Thomas, Jochen Schmitt, Joanne R Chalmers, Stefanie Deckert, Valeria Aoki, Elke Weisshaar, Jumoke Ahubelem Ojo, Åke Svensson.   

Abstract

This study investigated the perspective of international patients on individual symptoms of atopic dermatitis (eczema) in determining treatment response. A questionnaire was developed to evaluate the importance of symptoms from the patient's perspective. Patients were asked: "How important are these features in deciding whether or not a treatment is working?", and rated symptoms on a 5-point Likert scale. Patients were approached via Harmonising Outcome Measures for Eczema (HOME) collaborators and self-selected to take part in the on-line survey. Patients from 34 countries (n = 1,111) completed the survey; of these, 423 (38.3%) were parents of children with eczema. Nine items were rated as being "quite important" or "very important" by more than 80% of the respondents: itch, pain/soreness, skin feels hot or inflamed, bleeding, involvement of visible or sensitive body sites, cracks, sleep difficulties, amount of body affected, and weeping/oozing. These results may be of use in determining the face validity of scales from a cross-cultural patients' perspective.

Entities:  

Mesh:

Year:  2017        PMID: 27305646     DOI: 10.2340/00015555-2480

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  11 in total

1.  Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.

Authors:  Eric L Simpson; Emma Guttman-Yassky; David J Margolis; Steven R Feldman; Abrar Qureshi; Tissa Hata; Vera Mastey; Wenhui Wei; Laurent Eckert; Jingdong Chao; Renée J G Arnold; Tiffany Yu; Francis Vekeman; Mayte Suárez-Fariñas; Abhijit Gadkari
Journal:  JAMA Dermatol       Date:  2018-08-01       Impact factor: 10.282

Review 2.  Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics.

Authors:  Shawn G Kwatra; Laurent Misery; Claire Clibborn; Martin Steinhoff
Journal:  Clin Transl Immunology       Date:  2022-05-09

3.  Prevalence of Itch in German Schoolchildren: A Population-based Study.

Authors:  Grigorios Theodosiou; Theresa Nissen; Elke Weisshaar; Sandra Plachta-Danielzik; Matthias Augustin; Sonja Ständer; Laura B Von Kobyletzki; Regina Fölster-Holst
Journal:  Acta Derm Venereol       Date:  2022-05-19       Impact factor: 3.875

4.  Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.

Authors:  Jonathan I Silverberg; Anna M Tallman; William C Ports; Robert A Gerber; Huaming Tan; Michael A Zielinski
Journal:  Acta Derm Venereol       Date:  2020-06-11       Impact factor: 3.875

5.  Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.

Authors:  Jonathan I Silverberg; Eric L Simpson; Emma Guttman-Yassky; Michael J Cork; Marjolein de Bruin-Weller; Gil Yosipovitch; Laurent Eckert; Zhen Chen; Marius Ardeleanu; Brad Shumel; Thomas Hultsch; Ana B Rossi; Jennifer D Hamilton; Jamie M Orengo; Marcella Ruddy; Neil M H Graham; Gianluca Pirozzi; Abhijit Gadkari
Journal:  Dermatitis       Date:  2021-10-01       Impact factor: 4.845

6.  Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.

Authors:  Andrew Alexis; Marjolein de Bruin-Weller; Stephan Weidinger; Weily Soong; Sebastien Barbarot; Ileana Ionita; Fan Zhang; Hernan Valdez; Claire Clibborn; Natalie Yin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-17

7.  Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.

Authors:  Jonathan I Silverberg; H Chih-Ho Hong; Jacob P Thyssen; Brian M Calimlim; Avani Joshi; Henrique D Teixeira; Eric B Collins; Marjorie M Crowell; Scott J Johnson; April W Armstrong
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-18

8.  Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.

Authors:  J P Thyssen; G Yosipovitch; C Paul; S G Kwatra; C-Y Chu; M DiBonaventura; C Feeney; F Zhang; D Myers; R Rojo; H Valdez
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-12-13       Impact factor: 9.228

9.  The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.

Authors:  M de Bruin-Weller; A Gadkari; S Auziere; E L Simpson; L Puig; S Barbarot; G Girolomoni; K Papp; A E Pink; G Saba; T Werfel; L Eckert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-14       Impact factor: 6.166

10.  Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).

Authors:  L M Howells; J R Chalmers; S Gran; A Ahmed; C Apfelbacher; T Burton; L Howie; S Lawton; M J Ridd; N K Rogers; A V Sears; P Spuls; L von Kobyletzki; K S Thomas
Journal:  Br J Dermatol       Date:  2020-02-20       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.